2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1065
    Apelin-36(rat, mouse) 230299-95-3 98.59%
    Apelin-36(rat, mouse) is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-36(rat, mouse) binds to APJ receptors with an IC50 of 5.4 nM, and potently inhibits cAMP production with an EC50 of 0.52 nM. Apelin-36(rat, mouse) blocks entry of some HIV-1 and HIV-2 strains into NP-2/CD4 cells expressing APJ.
    Apelin-36(rat, mouse)
  • HY-P2742
    Ascorbate oxidase, Cucurbit sp. 9029-44-1
    Ascorbate oxidase, Cucurbit sp., also known as vitamin C oxidase, is a REDOX enzyme involved in the regulation of extracellular matrix. Ascorbate oxidase catalyzes the reaction of ascorbic acid and oxygen to produce dehydroascorbic acid.
    Ascorbate oxidase, Cucurbit sp.
  • HY-P2796
    Pyruvate decarboxylase 9001-04-1
    Pyruvate decarboxylase (PDC) is an enzyme that catalyses the decarboxylation of pyruvic acid to acetaldehyde. Pyruvate decarboxylase catalyses the non-oxidative conversion of pyruvate (or other 2-oxo acids) to acetaldehyde and CO2.
    Pyruvate decarboxylase
  • HY-P2839
    Heparinase 9025-39-2
    Heparinase (Heparinase I) degrades heparin to oligosaccharide or unsaturated disaccharide. Heparinase can be used in the preparation of low molecular weight heparin (LMWH).
    Heparinase
  • HY-P4685
    (Sar1,Ile4,8)-Angiotensin II 185461-45-4 98.23%
    (Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β.
    (Sar1,Ile4,8)-Angiotensin II
  • HY-Y0606
    (+)-Camphor-10-sulfonic acid 3144-16-9 ≥98.0%
    (+)-Camphor-10-sulfonic acid ((+)-10-Camphorsulfonic acid) is an effective pancreatic lipase (PL) inhibitor. (+)-Camphor-10-sulfonic acid is promising for research of obesity.
    (+)-Camphor-10-sulfonic acid
  • HY-100353
    C12-Ceramide 74713-60-3 99.82%
    C12-Ceramide (N-Lauroyl-D-erythro-sphingosine), a naturally occurring ceramide, is formed by hydrolysis of C12 sphingomyelin. C12-Ceramide can enhance the Doxorubicin toxicity in MDA-MB-231 cells. C12-Ceramide also can be used to diagnose types A and B Niemann-Pick disease.
    C12-Ceramide
  • HY-101325
    (S,S)-BRL-37344 sodium 127299-93-8 ≥99.0%
    (S,S)-BRL-37344 sodium is an isomer of BRL-37344 (HY-101325B). BRL-37344 is a β-adrenoceptor agonist with EC50 values of 5.3, 18 and 570 nM for β3, β2 and β1. BRL-37344 induces concentration-dependent increases in atria1 rate, relaxation of guinea pig trachea and lipolysis of brown adipocytes.
    (S,S)-BRL-37344 sodium
  • HY-103322
    6-Bnz-cAMP sodium salt 1135306-29-4 ≥98.0%
    6-Bnz-cAMP sodium, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K+ channel. 6-Bnz-cAMP sodium does not activate the Epac signaling pathway. It inhibits the bTREK-1 K+ channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP sodium activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. It can be used in studies related to bone tissue repair and regeneration.
    6-Bnz-cAMP sodium salt
  • HY-107580
    GPR109 receptor agonist-1 306935-41-1 99.94%
    GPR109 receptor agonist-1 is a highly selective agonist of the human orphan G protein-coupled receptor GPR109b, and does not activate the mouse homologous receptor PUMA-G. GPR109 receptor agonist-1 functionally modulates the human GPR109b receptor via the cAMP signaling pathway, with an EC50 of 400 nM. GPR109 receptor agonist-1 inhibits isoproterenol (HY-B0468)-stimulated lipolysis in human subcutaneous adipocytes, with efficacy comparable to that of Niacin (HY-B0143), and does not act on β-adrenergic receptors. GPR109 receptor agonist-1 can be used in studies related to dyslipidemia and atherosclerosis.
    GPR109 receptor agonist-1
  • HY-107642
    MA-2029 287206-61-5 98.94%
    MA-2029 is a selective, orally active, and competitive motilin receptor antagonist (IC50=4.9 nM). MA-2029 is selective for the motilin receptor over various other receptors and ion channels. MA-2029 may be useful for gastrointestinal disorders associated with disturbed gastrointestinal motility.
    MA-2029
  • HY-108296
    Pirenoxine 1043-21-6
    Pirenoxine (Catalin K) is a potent antioxidant. Pirenoxine shows anti-presbyopic activity. Pirenoxine has the potential for the research of cataracts.
    Pirenoxine
  • HY-108571
    CP-775146 702680-17-9 98.70%
    CP-775146 is a selective PPARα agonist (Ki of 24.5 nM) that binds strongly to the PPARα ligand. CP-775146 has no observable affinity for PPARβ and PPARγ.CP-775146 shows hypolipidemic activity. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway.
    CP-775146
  • HY-108604
    Bisindolylmaleimide II 137592-45-1 99.96%
    Bisindolylmaleimide II is a general inhibitor of all PKC subtypes.
    Bisindolylmaleimide II
  • HY-110118
    Edaglitazone 213411-83-7 99.57%
    Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC50s of 35.6 nM and 1053 nM for PPARα and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity.
    Edaglitazone
  • HY-112619
    TES-991 1883602-20-7 99.65%
    TES-991 is a potent and selective human α Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) inhibitor, with an IC50 of 3 nM.
    TES-991
  • HY-112939
    Colestilan 95522-45-5
    Colestilan (MCI-196) is a non-absorbed, non-calcium-based phosphate binder and is also a non-metallic, anion exchange resin. Colestilan is orally active and can be used for hypercholesterolaemia research.
    Colestilan
  • HY-113079
    Argininic acid 157-07-3 ≥98.0%
    Argininic acid is an α-amino acid that is used in the biosynthesis of proteins.
    Argininic acid
  • HY-115938
    BEC2 1429614-99-2 98.0%
    BEC2 is an ester derivative of Baicalin, with good lipid-lowering activity. BEC2 can direct activate the carnitine palmitoyltransferase 1A (CPT1A).
    BEC2
  • HY-116895
    JJH260 1831135-30-8 98.35%
    JJH260 is AIG1inhibitor, and inhibit the fluorophosphonate reactivity and fatty acid esters of hydroxy fatty acid (FAHFA) hydrolysis activity of AIG1in HEK293T cells, with IC50 values of 0.50 μM and 0.57 μM, respectively.
    JJH260
Cat. No. Product Name / Synonyms Application Reactivity